Precancer of Uterine Cervix following Biologics - 03/05/15 08:52 PM
Strewth - http://ard.bmj.com/content/early/2015/03/05/annrheumdis-2014-206909?papetoc
Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with arthritis
René Cordtz1, Lene Mellemkjær2, Bente Glintborg1, Merete Lund Hetland3,4, Lene Dreyer1
+ Author Affiliations
1Department of Rheumatology, Copenhagen University Hospital Gentofte, Hellerup, Denmark
2Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
3DANBIO Registry and Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark
4Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Denmark
Correspondence to
René Lindholm Cordtz, Department of Rheumatology, Copenhagen University Hospital Gentofte, Entrance 5, 3rd floor, Kildegårdsvej 28, Hellerup 2900, Denmark; rcordtz@gmail.com
Published Online First 5 March 2015
Patients with rheumatoid arthritis (RA) are more frequent chronic carriers of high-risk human papilloma virus (HPV) strains compared with the background population—an important risk factor for developing cervical cancer—and patients with RA have an increased risk of high-grade cervical dysplasia (CD) and cervical cancer.1–3 Little is known about the safety of biological disease-modifying antirheumatic drug (bDMARD) treatment in arthritis patients with a history of premalignant lesions.
We aimed to investigate how often female patients with inflammatory arthritis (RA, ankylosing spondylitis, psoriatic arthritis or other) and a history of premalignant lesions of the uterine cervix developed cervical cancer or another HPV-associated cancer according to ever versus never exposure to bDMARDs.
The nationwide Danish DANBIO Registry started in 2000 and covers >90% of adults with rheumatological disease treated with bDMARDs in routine care.4 Since 2005, patients not treated with bDMARDs have also been registered. We linked 15 238 female patients identified in DANBIO …
What the... <shakes head> Sigh.
Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with arthritis
René Cordtz1, Lene Mellemkjær2, Bente Glintborg1, Merete Lund Hetland3,4, Lene Dreyer1
+ Author Affiliations
1Department of Rheumatology, Copenhagen University Hospital Gentofte, Hellerup, Denmark
2Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
3DANBIO Registry and Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark
4Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Denmark
Correspondence to
René Lindholm Cordtz, Department of Rheumatology, Copenhagen University Hospital Gentofte, Entrance 5, 3rd floor, Kildegårdsvej 28, Hellerup 2900, Denmark; rcordtz@gmail.com
Published Online First 5 March 2015
Patients with rheumatoid arthritis (RA) are more frequent chronic carriers of high-risk human papilloma virus (HPV) strains compared with the background population—an important risk factor for developing cervical cancer—and patients with RA have an increased risk of high-grade cervical dysplasia (CD) and cervical cancer.1–3 Little is known about the safety of biological disease-modifying antirheumatic drug (bDMARD) treatment in arthritis patients with a history of premalignant lesions.
We aimed to investigate how often female patients with inflammatory arthritis (RA, ankylosing spondylitis, psoriatic arthritis or other) and a history of premalignant lesions of the uterine cervix developed cervical cancer or another HPV-associated cancer according to ever versus never exposure to bDMARDs.
The nationwide Danish DANBIO Registry started in 2000 and covers >90% of adults with rheumatological disease treated with bDMARDs in routine care.4 Since 2005, patients not treated with bDMARDs have also been registered. We linked 15 238 female patients identified in DANBIO …
What the... <shakes head> Sigh.